1-6 of 6
Patrick M. Reagan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M. Riska, lzidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Grzegorz S. Nowakowski, Matthew J. Maurer
Journal: Blood Advances
Blood Adv (2024) 8 (16): 4414–4422.
https://doi.org/10.1182/bloodadvances.2024012838
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Clinical Trials & Observations
Armin Ghobadi, Javier Munoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2982–2990.
https://doi.org/10.1182/bloodadvances.2023011532
Published: 2024
Includes: Supplemental data
Journal Articles

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

Clinical Trials & Observations
Danielle S. Wallace, Clive S. Zent, Andrea M. Baran, Patrick M. Reagan, Carla Casulo, Geoffrey Rice, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2496–2503.
https://doi.org/10.1182/bloodadvances.2022009382
Published: 2023
Includes: Supplemental data
Journal Articles

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Clinical Trials & Observations
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Jeffrey M. Switchenko, Stephen M. Ansell, Nancy L. Bartlett, Kristie A. Blum, Amanda F. Cashen, Carla Casulo, Jonathan W. Friedberg, Patrick B. Johnston, Brad S. Kahl, John P. Leonard, Brian K. Link, Izidore S. Lossos, Peter Martin, Matt J. Maurer, Neha Mehta-Shah, Patrick M. Reagan, Jason R. Westin, Jean L. Koff, Christopher R. Flowers
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2745–2756.
https://doi.org/10.1182/bloodadvances.2021006504
Published: 2022
Includes: Supplemental data
Journal Articles

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4149–4155.
https://doi.org/10.1182/bloodadvances.2020003848
Published: 2021
Includes: Supplemental data
Journal Articles

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Clinical Trials & Observations
Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4898–4911.
https://doi.org/10.1182/bloodadvances.2020002394
Published: 2020
Includes: Supplemental data